We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will...
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.4 | -9.73236009732 | 4.11 | 4.42 | 3.7 | 28458 | 4.07677159 | CS |
| 4 | -0.13 | -3.38541666667 | 3.84 | 4.42 | 3.56 | 34165 | 3.93099487 | CS |
| 12 | -0.49 | -11.6666666667 | 4.2 | 5.83 | 3.42 | 41321 | 4.33903964 | CS |
| 26 | 0.51 | 15.9375 | 3.2 | 5.83 | 2.62 | 98482 | 3.71574165 | CS |
| 52 | -1.91 | -33.9857651246 | 5.62 | 6.09 | 1.66 | 118290 | 3.55027245 | CS |
| 156 | -29.32 | -88.7677868604 | 33.03 | 43.5499 | 1.66 | 185031 | 12.71016272 | CS |
| 260 | -22.05 | -85.597826087 | 25.76 | 95.375 | 1.66 | 189302 | 20.75159564 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
